Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, purchased 29,318 common shares at prices between $0.78 and $0.81, increasing Cerrone's stake from 37.70% to 37.72%.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, purchased 29,318 common shares at prices between $0.78 and $0.81, increasing Cerrone's stake from 37.70% to 37.72%. The company focuses on developing innovative drug delivery technologies for immunotherapies, with two lead candidates showing favorable safety and efficacy in clinical studies. Tiziana aims to enhance immunotherapy efficacy through alternative delivery methods such as nasal and oral routes.
Positive
- Gabriele Cerrone increased ownership stake in Tiziana from 37.70% to 37.72%.
- Tiziana's lead candidates have demonstrated favorable safety profiles in clinical studies.
Negative
- None.
Details
News Market Reaction – TLSA
The recorded move for TLSA in the trading session of this news was -33.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 29,318 common shares priced between
The acquisition takes Mr Cerrone's interests from
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.